Brief: Iovance Biotherapeutics Announces Updated Clinical Data For Lifileucel In Combination With Pembrolizumab In Frontline Advanced Melanoma
23/05/2024 23:50
May 23 (Reuters) - Iovance Biotherapeutics Inc IOVA.O :
* IOVANCE BIOTHERAPEUTICS INC - ANNOUNCED UPDATED CLINICAL
DATA
FOR LIFILEUCEL IN COMBINATION WITH PEMBROLIZUMAB IN FRONTLINE
ADVANCED MELANOMA
Source text for Eikon: ID:nGNX95pj75
Further company coverage: IOVA.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Iovance Biotherapeutics
See all newsBrief: Iovance Biotherapeutics Reports Inducement Grants
US RESEARCH ROUNDUP-BlackRock, Evercore, Goldman Sachs
Brief: Iovance Biotherapeutics Appoints Noah Berkowitz, M.D., Ph.D., As Chief Medical Officer
Iovance hits two-year high after raising annual revenue forecast
U.S. RESEARCH ROUNDUP- Berkshire Hathaway, Exxon Mobil, Honeywell Technologies